Third Quarter 2025 vs. Third Quarter 2024Revenue of $19.3 million compared to $19.4 million; Gross profit of $4.3 million compared to $4.2 million; Gross margin of 22.3% compared to 21.7%; Net income of $1.1 million compared to net income of $0.7 million; Earnings per share of $0.09 compared to earnings per share of $0.06; EBITDA(1) of $1.9 million compared to $1.7 million.Nine Months 2025 vs. Nine Months 2024Revenue of $49.8 million compared to $59.3 million; Gross profit of $6.6 million compared to $12.9 million; Gross margin of 13.3% (20.4% excluding A-10 Program impact) compared to 21.7%; Net (loss) income of $(1.5) million compared to net income of $2.3 million; (Loss) earnings per share of $(0.12) compared to earnings per share of $0.19; Adjusted EBITDA(1) of $(0.6) million ($3.9 million excluding A-10 Program impact) compared...

Company continues growth momentum, reduces net loss 90.3% over prior year quarter, and accelerates path to Adjusted EBITDA breakevenImproving Fiscal Q2 and Record Six-Month RevenueRevenue increased 25.9% quarter-over-quarter and 15.2% year-over-year to $13.7 million; six-month revenue rose 18.0% to $24.5 million, reporting a record first half and best quarter in the last 12 months.Sharply Reduced Net Loss and Fifth Straight Quarter of Adjusted EBITDA1 ImprovementQ2 net loss narrowed to $(2.1) million from $(21.8) million the same quarter last year, a 90.3% year-over-year improvement. Adjusted EBITDA loss improved to $(1.1) million from $(2.1) million from the prior year quarter — a 48.6% year-over-year improvement.Balance Sheet Strengthened Through Premium Capital RaisesOver $9 million in additional capital was raised at premiums...

BOSTON, Nov. 14, 2025 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the third quarter 2025. On October 30, 2025, the Company announced that its Board of Directors determined, after extensive consideration of the Company’s development pipeline and current market conditions, to discontinue development of solnerstotug and initiate a comprehensive review of strategic alternatives aimed at maximizing shareholder value. The Company is exploring a range of strategic alternatives that may include, among other options, a sale of assets, licensing arrangements, collaborations, a sale of the Company, a business combination, a merger, or an orderly wind-down...

Hydroponic Basil, Potted Herbs, and Wheatgrass Accelerate; International Nutraceutical Sales Nearly Double Year-Over-Year Company’s Portfolio Optimization and Expansion into CEA-Informed, Better-For-You Shelf Stable Categories Pushes Market Penetration and Growth Conference Call to Be Held Today at 8:00 am ET. BELVIDERE, N.J., Nov. 14, 2025 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leading provider of controlled environment agriculture (CEA) solutions and sustainable, locally grown organic produce, today announced financial results for the third quarter ended September 30, 2025. The third quarter is traditionally the slowest of the year for Edible Garden, however the results reflect the early benefits of the Company’s strategic evolution toward a CEA informed...

MERIDIAN, Idaho, Nov. 14, 2025 (GLOBE NEWSWIRE) — PCS Edventures!, Inc. (“PCSV”), a leading provider of TK-12 Science, Technology, Engineering and Mathematics (“STEM”) education programs, today announced results of operations for its second quarter of fiscal year 2026, which ended on September 30, 2025. Second Quarter FY 2026 Overview:Revenue decreased 32.5% to $1,529,503 in the second quarter of FY 2026 compared to the prior year. Gross margin of 58.0% in the second quarter of FY 2026 compared to 59.7% in the second quarter of FY 2025. Net income before income tax provision was $0.00 million in the second quarter of FY 2026 versus $0.55 million in the previous year same quarter. During the quarter, shares outstanding declined 3.3% as 3,967,283 shares were repurchased.Mike Bledsoe, President, commented, “This quarter marked...

APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma  MT-601 demonstrated 66% objective response rate with 50% complete response in relapsed Non-Hodgkin lymphoma (NHL) patients in the ongoing APOLLO study First patient treated in Off-the-Shelf program (RAPID study) investigating MAR-T cells in patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) cGMP manufacturing collaboration established with Cellipont Bioservices HOUSTON, Nov. 14, 2025 (GLOBE NEWSWIRE) — Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company developing next-generation T cell-based therapies, today reported corporate updates and financial results for the third quarter ended September 30, 2025. “Marker entered the second half of 2025 with strong...

MISSISSAUGA, Ontario, Nov. 14, 2025 (GLOBE NEWSWIRE) — Next Hydrogen Solutions Inc. (the “Company” or “Next Hydrogen”) (TSXV:NXH, OTC:NXHSF), a designer and manufacturer of electrolyzers, is pleased to report its financial results for the third quarter ended September 30, 2025. “Last week, we announced a transformative financing following the successful commissioning of our electrolyzer at the largest onsite hydrogen fueling station in Ontario. We view this as a testament to our proprietary electrolyzer technology for cost-effective clean hydrogen production,” said Raveel Afzaal, President & CEO of Next Hydrogen. “This financing, once closed, is expected to fully fund us to cashflow positive while enabling us to scale our existing product line and launch our larger product line. We will execute on a capital light strategy...

–-Commercially Launched ORLYNVAH™ in the United States in August 2025– –Extended Cash Runway into Q2 2026– –Company to host conference call today at 8:30amET– DUBLIN, Ireland and CHICAGO, Nov. 14, 2025 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company or Iterum), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the quarter ended September 30, 2025. “We are thrilled to have launched ORLYNVAH™ in the United States in August 2025 for the treatment of uncomplicated urinary tract infections (uUTIs),” said Corey Fishman, Chief Executive Officer of Iterum Therapeutics. “The significance of this milestone cannot...

HALIFAX, Nova Scotia, Nov. 14, 2025 (GLOBE NEWSWIRE) — NexLiving Communities Inc. (“NexLiving” or the “Company”) announced operating and financial results for the three-month and nine-month periods ended September 30, 2025. Stavro Stathonikos, President & CEO commented: “2025 has so far been a year of strong execution producing a milestone quarter for NexLiving. Q3 FFO per share was the highest ever, having increased +30% year-over-year, driven by both operational improvements and acquisition growth. In late Q2 we brought management of our Saint John portfolio in-house, resulting in a +13% increase in same-property NOI. Our recent Winnipeg acquisition is already contributing to FFO, and as construction progresses on our five-phase Ottawa townhome project, we expect to exercise our cashless option and add high-quality assets...